SCHEMBL2126473

SCHEMBL2126473

N#Cc1c[nH]n2c(Nc3ccc4c(c3)OCO4)c(-c3ccc(C(=O)O)cc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 14/20 0.43
▸ KDM5A P29375 2/20 0.42
▸ GAA P10253 9/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ TP53 P04637 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ KDM4E B2RXH2 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2124362 0.89 MAPT (0.43) MAPTKDM5AGAAMAPK1TP53
SCHEMBL2123121 0.87 MAPT (0.54) MAPTKDM5AGAAMAPK1TP53
SCHEMBL2123221 0.85 MAPT (0.55) MAPTGAAMAPK1TP53POLB
SCHEMBL2122218 0.83 MAOB (0.44) MAPTKDM5AGAAMAPK1TP53
SCHEMBL2876451 0.79 MAPT (0.54) MAPTGAAMAPK1TP53POLB
SCHEMBL2873341 0.78 TGFBR1 (0.45) MAPTGAATP53POLBKDM4E
SCHEMBL2124513 0.78 LMNA (0.41) MAPTKDM5AGAAMAPK1TP53
SCHEMBL2123625 0.76 KDM5A (0.48) MAPTKDM5AGAATP53POLB
SCHEMBL2125974 0.76 KDM5A (0.50) MAPTKDM5ATP53POLB
SCHEMBL2124809 0.76 KDM5A (0.53) MAPTKDM5ATP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK MAPT 4045/4885KDM5A 1592/4885GAA 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback